Company Overview

Exelixis, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of oncology therapeutics. The company operates primarily in the biopharmaceutical industry, with a strategic emphasis on targeted cancer therapies and immuno-oncology combinations. Exelixis generates the majority of its revenue from sales of its lead oncology drug, CABOMETYX (cabozantinib), as well as from collaboration revenues tied to licensing and development partnerships. The company serves oncologists, hospitals, specialty pharmacies, and healthcare systems primarily in the treatment of renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and other advanced solid tumors.

The company was founded in 1994 and initially focused on genomics and drug discovery technologies before evolving into a commercial-stage oncology company. Exelixis’ transition accelerated following the clinical and commercial success of cabozantinib-based therapies. The company has established a differentiated position through its expertise in tyrosine kinase inhibitor development, broad clinical trial programs, and strategic collaborations with major pharmaceutical companies. Its business model combines internally developed oncology assets with external licensing agreements designed to expand therapeutic indications and geographic reach.

Business Operations

Exelixis operates primarily through a single business segment focused on oncology therapeutics, though its operational activities span drug discovery, clinical development, regulatory affairs, manufacturing oversight, and commercial sales. The company’s flagship product, CABOMETYX, is approved across multiple oncology indications and represents the company’s primary revenue driver through product sales in the United States and royalty arrangements internationally. Exelixis also markets COMETRIQ, another formulation of cabozantinib approved for medullary thyroid cancer. Revenue is additionally generated through licensing agreements, milestone payments, and collaboration arrangements with pharmaceutical partners.

The company maintains partnerships with organizations including Ipsen, Takeda Pharmaceutical Company, and Bristol Myers Squibb for commercialization and combination therapy development. Exelixis retains significant intellectual property related to cabozantinib and its oncology pipeline. Clinical development activities include internally sponsored and partner-sponsored trials evaluating combinations with checkpoint inhibitors and next-generation oncology candidates. Operations are centered in the United States, while international commercialization activities are supported through regional licensing and distribution partnerships.

Strategic Position & Investments

Exelixis’ strategic direction centers on expanding its oncology portfolio beyond cabozantinib while maximizing the lifecycle and global market penetration of existing therapies. The company has invested heavily in clinical development programs involving combination regimens, earlier-line treatment settings, and new tumor indications. Management has emphasized capital allocation toward internal pipeline expansion, business development opportunities, and selective acquisitions or licensing arrangements designed to diversify long-term revenue sources.

The company has invested in next-generation oncology assets and precision medicine approaches through internal research initiatives and external collaborations. Exelixis has pursued licensing agreements involving small molecule therapeutics, antibody-drug conjugates, and immunotherapy-related technologies. Acquisitions and partnerships involving companies such as Cybrexa Therapeutics and development-stage oncology programs have supported broader pipeline diversification efforts. Exelixis has also continued expanding translational research capabilities and biomarker-driven clinical strategies to strengthen its competitive positioning within targeted oncology therapeutics.

Geographic Footprint

Exelixis is headquartered in Alameda, California, and its primary commercial operations are concentrated in the United States. The company maintains a growing international presence through strategic licensing agreements and commercialization partnerships across Europe, Japan, and other global markets. International sales exposure is primarily derived from royalties and milestone payments associated with ex-U.S. commercialization agreements.

The company’s therapies are marketed or under development across multiple continents through collaborations with regional pharmaceutical partners. Ipsen oversees commercialization activities for cabozantinib in regions outside the United States and Japan, while Takeda Pharmaceutical Company manages commercialization rights in Japan. Exelixis’ clinical trial infrastructure and development collaborations also extend into global oncology research centers, supporting multinational regulatory and development initiatives.

Leadership & Governance

Exelixis leadership has emphasized disciplined oncology-focused growth, lifecycle management of commercial therapies, and long-term investment in differentiated cancer therapeutics. The company’s governance structure reflects a combination of biotechnology research leadership, commercial pharmaceutical expertise, and public company operational oversight. Strategic priorities communicated in company filings and investor materials have consistently focused on scientific innovation, financial sustainability, and expansion of the oncology pipeline.

Key executives include:

• Michael M. Morrissey – President and Chief Executive Officer
• Christopher J. Senner – Executive Vice President and Chief Financial Officer
• Amy C. Peterson – Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer
• Dana Aftab – Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer
• Jeffrey Hessekiel – Executive Vice President and General Counsel
• Patrick J. Haley – Executive Vice President, Commercial

Information presented above is consistent with disclosures in SEC filings, company annual reports, investor presentations, and major financial and pharmaceutical industry reporting sources. Where reporting differed regarding partnership scope or pipeline terminology, information was limited to details consistently confirmed across public disclosures.